PPAR-gamma in Cushing's disease.
The majority of pituitary tumors that cause Cushing's disease are small (<1 cm diameter), and most disease morbidity is due to the effects of elevated, non-suppressible, ACTH levels that these tumors secrete. Tumor-derived ACTH leads to adrenal-derived steroid hypersecretion and results in many disabling and sometimes life-threatening symptoms including abnormal fat deposition, skin thinning, psychological disturbances, hypertension, diabetes, osteoporosis and muscle weakness. Cushing's disease is associated with high morbidity and ultimately mortality. In experienced specialized centers, 70% of corticotroph microadenomas can be successfully resected by transsphenoidal pituitary surgery. However, surgical "cure" rates for larger ACTH-secreting pituitary tumors are achieved in only 30% of cases, and recent reports highlight a significant recurrence rate after longer term follow-up even in smaller tumors. Post-surgical persistence of ACTH hypersecretion may require pituitary-directed radiation, but this treatment may take some time to be effective, and like extensive surgical pituitary tumor resection, ultimately leads to partial- or total hypopituitarism in approximately 80% of cases. Although hypercortisolism may be completely resolved by adrenalectomy, this procedure does not suppress, and may act as a stimulus to pituitary tumor growth, and is associated with other co-morbidity. Although some currently available drug-based treatments for Cushing's disease effectively control hypercortisolism, their drawback has been that they do not impact on pituitary tumor growth. Recent studies have identified the potential utility of peroxisome-proliferator activating receptor-gamma (PPAR-gamma) novel ligands in in vitro, and in vivo Cushing's disease models, and have paved the way for early clinical studies to develop novel therapeutic approaches in Cushing's disease.
Heaney
Anthony P
AP
Division of Endocrinology, Cedars-Sinai Research Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA. HeaneyA@cshs.org
D049913:ACTH-Secreting Pituitary Adenoma / Q000188:drug therapy / Q000473:pathology; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D003480:Cushing Syndrome / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008024:Ligands; D009361:Neoplasm Invasiveness; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism*; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy* / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000473:pathology; D045162:Thiazolidinediones / Q000627:therapeutic use
D008024:Ligands; D047495:PPAR gamma; D045162:Thiazolidinediones; D000324:Adrenocorticotropic Hormone; C089946:2,4-thiazolidinedione